Read, Watch or Listen

The Trump administration's surprise approval of leucovorin, a vitamin B derivative, as an autism treatment has sparked controversy. Experts, including the physician who initially suggested it, express concern over the lack of sufficient studies. Leading autism groups and researchers deem the supporting evidence weak and insufficient. While some small studies show potential benefits, larger controlled trials are needed. The FDA's decision to update the drug's label, potentially increasing prescriptions, raises further concerns among researchers who warn against premature adoption of unproven treatments. Online sources, including chatbots, are contributing to parental interest.

Prepared by Olivia Bennett and reviewed by editorial team.